HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story 6-month HIV PrEP makes coverage gains ...

On 14 July 2025, the World Health Organization (WHO) issued new guidelines recommending twice-yearly injectable lenacapavir as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention.

Introduction Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products ...

The Rwanda Biomedical Center (RBC) said last week that the government plans to introduce lenacapavir, a long-acting ...

We're at a crossroads where an end to the epidemic is truly within reach. So what happens next?

Health experts warn new HIV preventive jab does not protect against other STIs, pregnancyHealth experts are welcoming the registration of a twice-yearly injection to prevent HIV, while warning that ...

Accusing the state of “reckless maladministration” of the lethal-injection process, an attorney for condemned killer Ronald ...

GSK is hoping that its accelerated R&D strategy and new launches will help offset the impact of upcoming patent expiries within its portfolio.

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So it works quite well as a VEGFR inhibitor and it is de-risked in that sense.

GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect ...